NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Abstracts demonstrate reversal of resistance to PD1 checkpoint blockade and predictive AI model of HCC survival rateSARASOTA, Fla. and MIAMI, Oct. 31, 2024 — NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to...
Skip to content